LYRA

Lyra Therapeutics, Inc. (LYRA) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Financial Risk

Liquidity remains adequate with a current ratio of 1.71 and cash ratio of 1.67.

Profitability remains deeply negative, with TTM operating margin at -77.9% and net margin at -72.7%.

Leverage remains elevated relative to market value, with debt-to-market-cap at 85.2x and debt-to-assets at 83.8%.

Operational Risk

Revenue productivity remains weak, with asset turnover at 0.01x and fixed-asset turnover at 0.02x.

Operating cash flow remains negative, with OCF per share at -1.86 and free cash flow per share at -1.87.

R&D intensity remains high at 46.3% of revenue, which supports innovation but also keeps near-term burn elevated.

Market Valuation Risk

Valuation remains stretched on sales, with EV/sales at 37.0x despite negative earnings and cash flow.

Price-to-book remains negative at -0.29, reflecting a weak balance-sheet/equity profile.

No recent news was provided to indicate a new catalyst or change in market sentiment.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lyra Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →